FBR Capital Initiates Coverage on TESARO Inc(NASDAQ:TSRO). The shares have been rated Outperform. The rating by FBR Capital was issued on Apr 13, 2016.
In a different note, Citigroup said it Initiates Coverage on TESARO Inc, according to a research note issued on Mar 17, 2016. The shares have been rated ‘Buy’ by the firm. SunTrust Robinson Humphrey said it Initiates Coverage on TESARO Inc, according to a research note issued on Mar 1, 2016. The shares have been rated ‘Buy’ by the firm. Lake Street said it Initiates Coverage on TESARO Inc, according to a research note issued on Feb 5, 2016. The shares have been rated ‘Buy’ by the firm. Wedbush said it Initiates Coverage on TESARO Inc, according to a research note issued on Jan 20, 2016. In the research note, the firm Announces the price-target to $72 per share. The shares have been rated ‘Outperform’ by the firm.
TESARO Inc (TSRO) made into the market gainers list on Fridays trading session with the shares advancing 1.02% or 0.44 points. Due to strong positive momentum, the stock ended at $43.71, which is also near the day’s high of $44.27. The stock began the session at $43.29 and the volume stood at 7,38,423 shares. The 52-week high of the shares is $66.95 and the 52 week low is $29.51. The company has a current market capitalization of $1,761 M and it has 4,02,83,470 shares in outstanding.
TESARO Inc(TSRO) last announced its earnings results on Feb 25, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $230.00K. Analysts had an estimated revenue of $3.45M. Earnings per share were $-1.89. Analysts had estimated an EPS of $-1.63.
Several Insider Transactions has been reported to the SEC. On Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price.Also, On Mar 18, 2016, Arnold L Oronsky (director) purchased 142,085 shares at $35.19 per share price.On Mar 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $43.54 per share price, according to the Form-4 filing with the securities and exchange commission.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.